Selecting COVID‐19 convalescent plasma for neutralizing antibody potency using a high‐capacity SARS‐CoV‐2 antibody assay

BACKGROUND: Efficacy of COVID‐19 convalescent plasma (CCP) is hypothesized to be associated with the concentration of neutralizing antibodies (nAb) to SARS‐CoV‐2. High capacity serologic assays detecting binding antibodies (bAb) have been developed; nAb assays are not adaptable to high‐throughput te...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Transfusion
Main Authors: Goodhue Meyer, Erin, Simmons, Graham, Grebe, Eduard, Gannett, Michael, Franz, Sergej, Darst, Orsolya, Di Germanio, Clara, Stone, Mars, Contestable, Paul, Prichard, Alicia, Reik, Rita, Vassallo, Ralph, Young, Pampee, Busch, Michael P., Williamson, Phillip, Dumont, Larry J.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2021
Assuntos:
Donor Infectious Disease Testing
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013397/
https://ncbi.nlm.nih.gov/pubmed/33554362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/trf.16321
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares